Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.66 |
| ▸ | MTOR | P42345 | 15/20 | 0.66 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.54 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.48 |
| ▸ | RICTOR | Q6R327 | 2/20 | 0.44 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.44 |
| ▸ | MAPKAP1 | Q9BPZ7 | 2/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103147 | 0.89 | PIK3CA (0.53) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL4439746 | 0.89 | PIK3CA (0.52) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL466335 | 0.88 | PIK3CA (0.52) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL4438164 | 0.88 | PIK3CA (0.67) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL21054518 | 0.85 | PIK3CA (0.53) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL4437471 | 0.85 | MTOR (0.69) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL4555628 | 0.84 | PIK3CA (0.48) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL4440996 | 0.84 | PIK3CA (0.48) | PIK3CAMTORPIK3R1PIK3CDPIK3CG | |
| SCHEMBL14034104 | 0.84 | NPY5R (0.57) | PIK3CAMTORPIK3R1 | |
| SCHEMBL1862105 | 0.83 | MTOR (0.53) | PIK3CAMTORPIK3R1PIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2405916-B1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH INC (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9487533-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9335320-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-2114950-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20130345217-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-20130330765-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8604014-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use | GENENTECH, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-8536161-B2 | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies | GENENTECH, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8450315-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | GENENTECH, INC. | 2010-09-16 | — | — | US | disclosed |
| EP-2205242-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | Genentech, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2114950-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-2046799-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Genentech, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2009036082-A2 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | GENENTECH, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090098135-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885MTOR 17/4885PIK3R1 14/4885 |
| US-20100233164-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF HEMATOPOIETIC MALIGNANCIES | PIK3CA, PIK3CD, MCL1 | PIK3CA 1/4885MTOR 33/4885PIK3R1 15/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | PIK3CA 1/4885MTOR 43/4885PIK3R1 27/4885 |
| US-20130345217-A1 | COMBINATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND CHEMOTHERAPEUTIC AGENTS, AND METHODS OF USE | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885MTOR 17/4885PIK3R1 14/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885MTOR 11/4885PIK3R1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.